Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue: −31.8%
EPS: −123.9%
Free cash flow: −268.5%
Total debt: +52.6%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%

Follow LGND

Alert me

Market cap: $6.0B
P/E: 116×
Fwd P/E: 88.3×
Dividend yield: —
F-score: 6/9
Altman Z: 5.45
Beneish M: −4.02
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Ligand Pharmaceuticals Incorporated (LGND) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a P/S ratio of 23.6×. Over the past ten years it has ranged from 4.0× (June 2022) to 25.4× (October 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LGND/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Ligand Pharmaceuticals Incorporated P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LGND/metrics/ps-ratio">Ligand Pharmaceuticals Incorporated (LGND) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	13.6×	16.31%
FY2024	11.7×	23.10%
FY2023	9.5×	67.83%
FY2022	5.7×	(24.63%)
FY2021	7.5×	8.06%
FY2020	7.0×	(40.24%)
FY2019	11.7×	44.21%
FY2018	8.1×	(44.73%)
FY2017	14.6×	5.46%
FY2016	13.9×	(25.46%)

Period	P/S ratio	Change
Sep 2026	24.6×	12.55%
Jun 2026	21.8×	50.92%
Mar 2026	14.5×	6.04%
Dec 2025	13.6×	(1.20%)
43 more quarters	Free account

Against its own ten years

Low 4.0× High 25.4×

Ten-year median 12.0×

Current reading's percentile 99

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
IMVT Immunovant, Inc. compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
PTCT PTC Therapeutics, Inc. compare	4.8×
IONS Ionis Pharmaceuticals, Inc. compare	7.4×
MIRM Mirum Pharmaceuticals, Inc. compare	9.2×
LGND Ligand Pharmaceuticals Incorporated	23.6×
CGON CG Oncology, Inc. compare	919×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Ligand Pharmaceuticals Incorporated (LGND) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LGND

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LGND

Stockrow Weekly